|
1
|
Roy Choudhury S, Karmakar S, Banik NL and
Ray SK: Targeting angiogenesis for controlling neuroblastoma. J
Oncol. 2012:7820202012.PubMed/NCBI
|
|
2
|
Bareschino MA, Schettino C, Colantuoni G,
Rossi E, Rossi A, Maione P, Ciardiello F and Gridelli C: The role
of antiangiogenetic agents in the treatment of breast cancer. Curr
Med Chem. 18:5022–5032. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lyons J III, Anthony CT and Woltering EA:
The role of angiogenesis in neuroendocrine tumors. Endocrinol Metab
Clin North Am. 39:839–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rössler J, Monnet Y, Farace F, Opolon P,
Daudigeos-Dubus E, Bourredjem A, Vassal G and Geoerger B: The
selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor
activity in human neuroblastoma xenografts. Int J Cancer.
128:2748–2758. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cook KM and Figg WD: Angiogenesis
inhibitors: Current strategies and future prospects. CA Cancer J
Clin. 60:222–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang Y and Hyder SM: Proliferation of
endothelial and tumor epithelial cells by progestin-induced
vascular endothelial growth factor from human breast cancer cells:
Paracrine and autocrine effects. Endocrinology. 146:3632–3641.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brignole C, Marimpietri D, Pastorino F,
Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A,
Corrias MV, et al: Effect of bortezomib on human neuroblastoma cell
growth, apoptosis, and angiogenesis. J Natl Cancer Inst.
98:1142–1157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Segerström L, Fuchs D, Bäckman U,
Holmquist K, Christofferson R and Azarbayjani F: The anti-VEGF
antibody bevacizumab potently reduces the growth rate of high-risk
neuroblastoma xenografts. Pediatr Res. 60:576–581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blask DE, Sauer LA and Dauchy RT:
Melatonin as a chronobiotic/anticancer agent: Cellular,
biochemical, and molecular mechanisms of action and their
implications for circadian-based cancer therapy. Curr Top Med Chem.
2:113–132. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cos S and Sánchez-Barceló EJ: Melatonin
and mammary pathological growth. Front Neuroendocrinol. 21:133–170.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cos S and Sánchez-Barceló EJ: Melatonin,
experimental basis for a possible application in breast cancer
prevention and treatment. Histol Histopathol. 15:637–647.
2000.PubMed/NCBI
|
|
12
|
Hill SM and Blask DE: Effects of the
pineal hormone melatonin on the proliferation and morphological
characteristics of human breast cancer cells (MCF-7) in culture.
Cancer Res. 48:6121–6126. 1988.PubMed/NCBI
|
|
13
|
Cos S, Fernández R, Güézmes A and
Sánchez-Barceló EJ: Influence of melatonin on invasive and
metastatic properties of MCF-7 human breast cancer cells. Cancer
Res. 58:4383–4390. 1998.PubMed/NCBI
|
|
14
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ:
Estrogen-signaling pathway: A link between breast cancer and
melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alonso-González C, González A, Mazarrasa
O, Güezmes A, Sánchez-Mateos S, Martínez-Campa C, Cos S,
Sánchez-Barceló EJ and Mediavilla MD: Melatonin prevents the
estrogenic effects of sub-chronic administration of cadmium on mice
mammary glands and uterus. J Pineal Res. 42:403–410. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cos S, González A, Güezmes A, Mediavilla
MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ:
Melatonin inhibits the growth of DMBA-induced mammary tumors by
decreasing the local biosynthesis of estrogens through the
modulation of aromatase activity. Int J Cancer. 118:274–278. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cos S, González A, Martínez-Campa C,
Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Melatonin
as a selective estrogen enzyme modulator. Curr Cancer Drug Targets.
8:691–702. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
González A, Cos S, Martínez-Campa C,
Alonso-González C, Sánchez-Mateos S, Mediavilla MD and
Sánchez-Barceló EJ: Selective estrogen enzyme modulator actions of
melatonin in human breast cancer cells. J Pineal Res. 45:86–92.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martínez-Campa C, González A, Mediavilla
MD, Alonso-González C, Alvarez-García V, Sánchez-Barceló EJ and Cos
S: Melatonin inhibits aromatase promoter expression by regulating
cyclooxygenases expression and activity in breast cancer cells. Br
J Cancer. 101:1613–1619. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gerber HP, McMurtrey A, Kowalski J, Yan M,
Keyt BA, Dixit V and Ferrara N: Vascular endothelial growth factor
regulates endothelial cell survival through the
phosphatidylinositol 3-kinase/Akt signal transduction pathway.
Requirement for Flk-1/KDR activation. J Biol Chem. 273:30336–30343.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gingis-Velitski S, Zetser A, Flugelman MY,
Vlodavsky I and Ilan N: Heparanase induces endothelial cell
migration via protein kinase B/Akt activation. J Biol Chem.
279:23536–23541. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gu Q, Wang D, Wang X, Peng R, Liu J, Jiang
T, Wang Z, Wang S and Deng H: Basic fibroblast growth factor
inhibits radiation-induced apoptosis of HUVECs. I. The PI3K/AKT
pathway and induction of phosphorylation of BAD. Radiat Res.
161:692–702. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic
effects of melatonin in endothelial cell cultures. Microvasc Res.
87:25–33. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bäckman U, Svensson A and Christofferson
R: Importance of vascular endothelial growth factor A in the
progression of experimental neuroblastoma. Angiogenesis. 5:267–274.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Biedler JL, Helson L and Spengler BA:
Morphology and growth, tumorigenicity, and cytogenetics of human
neuroblastoma cells in continuous culture. Cancer Res.
33:2643–2652. 1973.PubMed/NCBI
|
|
27
|
Sánchez-Barceló EJ, Cos S, Mediavilla D,
Martínez-Campa C, González A and Alonso-González C:
Melatonin-estrogen interactions in breast cancer. J Pineal Res.
38:217–222. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lissoni P, Rovelli F, Malugani F, Bucovec
R, Conti A and Maestroni GJ: Anti-angiogenic activity of melatonin
in advanced cancer patients. Neuro Endocrinol Lett. 22:45–47.
2001.PubMed/NCBI
|
|
29
|
Dai M, Cui P, Yu M, Han J, Li H and Xiu R:
Melatonin modulates the expression of VEGF and HIF-1α induced by
CoCl2 in cultured cancer cells. J Pineal Res.
44:121–126. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Park SY, Jang WJ, Yi EY, Jang JY, Jung Y,
Jeong JW and Kim YJ: Melatonin suppresses tumor angiogenesis by
inhibiting HIF-1α stabilization under hypoxia. J Pineal Res.
48:178–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cui P, Yu M, Peng X, Dong L and Yang Z:
Melatonin prevents human pancreatic carcinoma cell PANC-1-induced
human umbilical vein endothelial cell proliferation and migration
by inhibiting vascular endothelial growth factor expression. J
Pineal Res. 52:236–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Regulation of
vascular endothelial growth factor by melatonin in human breast
cancer cells. J Pineal Res. 54:373–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
García-Santos G, Antolín I, Herrera F,
Martín V, Rodríguez-Blanco J, del Pilar Carrera M and Rodríguez C:
Melatonin induces apoptosis in human neuroblastoma cancer cells. J
Pineal Res. 41:130–135. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan Y and Niles LP: Epigenetic mechanisms
of melatonin action in human SH-SY5Y neuroblastoma cells. Mol Cell
Endocrinol. 402:57–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wongprayoon P and Govitrapong P: Melatonin
attenuates methamphetamine-induced neuroinflammation through the
melatonin receptor in the SH-SY5Y cell line. Neurotoxicology.
50:122–130. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cos S, Martínez-Campa C, Mediavilla MD and
Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7
human breast cancer cells. J Pineal Res. 38:136–142. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sainz RM, Mayo JC, Tan DX, León J,
Manchester L and Reiter RJ: Melatonin reduces prostate cancer cell
growth leading to neuroendocrine differentiation via a receptor and
PKA independent mechanism. Prostate. 63:29–43. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Alvarez-García V, González A,
Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes
in the desmoplastic reaction in breast cancer by regulating
cytokine production. J Pineal Res. 52:282–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
González A, Alvarez-García V,
Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes
differentiation of 3T3-L1 fibroblasts. J Pineal Res. 52:12–20.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Longatti P, Perin A, Rizzo V, Comai S,
Giusti P and Costa CV: Ventricular cerebrospinal fluid melatonin
concentrations investigated with an endoscopic technique. J Pineal
Res. 42:113–118. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Maestroni GJ and Conti A: Melatonin in
human breast cancer tissue: Association with nuclear grade and
estrogen receptor status. Lab Invest. 75:557–561. 1996.PubMed/NCBI
|
|
42
|
Dvorak HF, Weaver VM, Tlsty TD and Bergers
G: Tumor microenvironment and progression. J Surg Oncol.
103:468–474. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Staton CA, Stribbling SM, Tazzyman S,
Hughes R, Brown NJ and Lewis CE: Current methods for assaying
angiogenesis in vitro and in vivo. Int J Exp Pathol. 85:233–248.
2004. View Article : Google Scholar : PubMed/NCBI
|
